Navigation Links
Mederi Therapeutics Closes Funding of $18.5 Million
Date:12/23/2013

GREENWICH, Conn., Dec. 23, 2013 /PRNewswire/ -- Mederi Therapeutics Inc. announced today the closing on $18.5 million, comprised of Series B preferred stock and venture debt. Participating in this round were Acadia Woods Partners, LLC, Respiratory Diagnostics Inc., a subsidiary of Bio-Rad Laboratories, Inc., as well as a group of high net worth equity investors. Venture debt was provided by Horizon Technology Finance. The funds will be used to support and expand on the rapidly growing use of Mederi's Stretta therapy for Gastroesophageal Reflux Disease (GERD) and Secca therapy for Bowel Incontinence.

The overwhelming body of clinical data supporting Stretta's safety, efficacy and durability of effect has led to Mederi's rapid expansion. "Many device start-up companies launch with large sales forces and deep marketing budgets before gaining traction with clinical data and reimbursement. Mederi has strategically built sales and marketing as we gained such traction," said Will Rutan, CEO of Mederi. "This conservative approach has paid off, resulting in expanding insurance coverage domestically and abroad, significant growth in 2013, and product availability in almost 40 countries on a relatively small amount of investor capital."

"We are very pleased to have the support of all of our original investors plus a select new group, as well as the growing support of the medical community in our efforts to mainstream these safe and effective, minimally invasive therapies," continued Rutan.

The Value of a Safe, Effective, Low Cost Option
Mederi's radiofrequency treatments provide value to payers, providers and patients by offering safe, effective, durable and low-cost therapies.  Approximately 40 million Americans suffer from GERD, and 30% of those don't fully respond to medications. Stretta therapy for GERD is backed by more than 32 clinical studies showing up to 10 years of safe, durable s
'/>"/>

SOURCE Mederi Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. SkilaMederi and Qforma Announce Merger
2. SkilaMederi Names Ray Joske as Chief Commercial Officer
3. Aratana Therapeutics Provides 2013 Development Update
4. 2013 Report on the International Pain Management Therapeutics Market - Includes Forecast to 2018
5. Spark Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference
6. Updated Financial Standings, Company Announcements, and Customer-Centered Suggestions - Research Report on Perrigo, Thermo Fisher, DaVita, United Therapeutics, and Keryx Biopharmaceuticals
7. Sorrento Therapeutics Completes Acquisition of Concortis Biosystems
8. Portfolio Expansions, Product Data, and Announcements by Healthcare Companies - Research Report on Life Technologies, OncoMed, Halozyme Therapeutics, Infinity, and PTC Therapeutics
9. Circuit Therapeutics and Boehringer Ingelheim announce signature of a research partnership agreement to discover new approaches to treating psychiatric disorders
10. Cell Therapeutics Receives Remaining $5 million Under Existing Loan Financing Agreement
11. Halozyme Therapeutics Announces Executive Transitions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... Mass., July 29, 2014 Cynosure, Inc. ... markets laser- and light-based aesthetic treatment systems for high-volume ... ended June 30, 2014. Second-quarter 2014 financial results incorporate ... on June 24, 2013. Second-Quarter ... increased 45% to $72.6 million , Non-GAAP net ...
(Date:7/29/2014)... 29, 2014   ... will present data from a Phase I clinical trial ... or stop Parkinson,s disease progression. The Michael J. Fox ... and will discuss the impact of the results for ... Thursday, July 31, 2014       ...
(Date:7/29/2014)... 2014  Drug development for hepatitis C virus ... and the intense need for curative therapy in ... underway as the market moves away from protease ... interferon-free oral therapies. Logo - ... blockbuster Sovaldi is the first of these novel ...
Breaking Medicine Technology:Cynosure Reports Second-Quarter 2014 Financial Results 2Cynosure Reports Second-Quarter 2014 Financial Results 3Cynosure Reports Second-Quarter 2014 Financial Results 4Cynosure Reports Second-Quarter 2014 Financial Results 5Cynosure Reports Second-Quarter 2014 Financial Results 6Cynosure Reports Second-Quarter 2014 Financial Results 7Cynosure Reports Second-Quarter 2014 Financial Results 8Cynosure Reports Second-Quarter 2014 Financial Results 9Cynosure Reports Second-Quarter 2014 Financial Results 10Cynosure Reports Second-Quarter 2014 Financial Results 11Cynosure Reports Second-Quarter 2014 Financial Results 12Reminder/Media Advisory/AFFiRiS AG Presents Early Clinical Data on a First-of-its-Kind Parkinson's Disease Vaccine 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 2A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 3A Treatment Revolution is Underway: All-Oral Therapies Transform Global Hepatitis C Antiviral Market 4
... May 2, 2012 Janssen Research & Development, LLC, ... Drug Applications (sNDAs) to the U.S. Food and Drug ... ® (rivaroxaban), an oral anticoagulant, to treat patients ... and prevention of recurrent venous thromboembolism (VTE). ...
... Official journal of the American Association for ... of scientific, technical and medical information products and services, announces ... American Association for Geriatric Psychiatry (AAGP) to publish ... AJGP ) beginning in January 2013. "We are ...
Cached Medicine Technology:Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 2Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 3Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 4Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 5Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 6Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 7Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism 8Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 2Elsevier Selected as New Publisher of The American Journal of Geriatric Psychiatry 3
(Date:7/29/2014)... July 29, 2014 truBrain has created ... provided by energy drinks. Think Drinks , available ... that creates optimal conditions for memory, complex reasoning and ... hopes to raise $50,000 over the course of the ... mental boost and have compounding effects over time when ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Outsourced ... of tripling in the number of hospitals contracting ... 1, 2015 deadline, according to the recently published ... physician leaders, found in the reports “Top Ranked ... hospitals now outsource Clinical documentation audit, review and ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 Biocides are ... and control bacteria or fungi growth and to prevent ... within the material and its surface. It is used ... wood preservation, food and beverage, paints and coatings. It ... and sanitizers, as well as in industrial applications to ...
(Date:7/29/2014)... increasing use of electronic medical records and health ... a computerized version of the preventive care guidelines ... new study, researchers from the Indiana University School ... substantial work lies ahead to convert the American ... prompts for physicians, but the payoff has the ...
(Date:7/29/2014)... 29, 2014 The Latin American poultry feed ... with analysis and forecast of revenue. The poultry feed and ... from $25,273.3 million and $647.2 million in 2013 to $34,024.0 ... 6.1% from 2013 to 2018, respectively. , To get an ... the TOC of the Latin American poultry feed and feed ...
Breaking Medicine News(10 mins):Health News:Focus- and Productivity-Enhancing Beverage Launches Crowdfunding Campaign on Indiegogo 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 2Health News:Clinical Documentation Improvement Heats Up as Half of US Hospitals Make 2015 Preparations for ICD-10, the Rest to Rely on Outsourcers, Black Book Survey Reveals 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 2Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 3Health News:North America Biocides Market is Expected to Reach 890.3 KT in 2016 - New Report by MicroMarket Monitor 4Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 2Health News:Study: Pediatric preventive care guidelines need retooling for computerized format 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 2Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 3Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Latin America Poultry Feed Market is Expected to Reach $870.1 Million in 2018 - New Report by MicroMarket Monitor 5
... be done without destroying embryo , , WEDNESDAY, July 9 ... in developing human embryonic stem cells earlier in the ... embryo, so the whole embryo is not destroyed. , ... European Society of Human Reproduction & Embryology annual conference ...
... Chest Pain Centers (SCPC) have been shown to perform ... Centers for Medicare and Medicaid Services (CMS) as compared ... by an Emory University researcher. , The ... director for observation medicine in the Emory University School ...
... Holdings, Inc.,(NYSE and SWX: ZMH) announced today its second ... live over the Internet on,Thursday, July 24, 2008, at ... results will be made available at 7:00 a.m. the,morning ... can be accessed via Zimmer,s Investor Relations,website at ...
... it comes to the attractiveness of orthodontic braces, less metal ... of the public,s attitude about the attractiveness of various styles ... no visible metal were considered the most attractive. Braces that ... were a less desirable option, and braces with metal brackets ...
... WEDNESDAY, July 9 (HealthDay News) -- Being born extremely underweight ... as an adult. , A study published in the July ... were born at extremely low birth weights were more likely ... had been born at normal weights. , And that ...
... - DaVita Medical Missions Reaches Out to Patients in Need of ... ... Bridge of Life - DaVita,Medical Missions(TM), a non-profit organization founded by DaVita ... to its newest dialysis clinic in India in late,June. The new clinic ...
Cached Medicine News:Health News:New Technique Harvests Stem Cells at Earlier Stage 2Health News:New Technique Harvests Stem Cells at Earlier Stage 3Health News:Chest pain center accreditation linked with better outcomes in heart attack patients 2Health News:Survey: Most effective dental braces are least attractive 2Health News:Survey: Most effective dental braces are least attractive 3Health News:Do Underweight Newborns Make for Shy Adults? 2Health News:U.S. Non-Profit Brings Life-Saving Dialysis Treatment to India 2Health News:U.S. Non-Profit Brings Life-Saving Dialysis Treatment to India 3
... Chalam 15° Prism are designed ... are recommended for tractional retinal ... Rhegmatogenus retinal detachment. They can ... and other midperipheral laser applications. ...
... The High-Mag 1.5x ... internal limiting membrane peeling ... optic nerve neurotomy, sheathotomy ... traditional macular edema and ...
... visualization of virtually the entire retina including ... of the lens on the eye. It ... giant retinal tears, diagnosing and treating anterior ... retina in a vitreous cavity filled with ...
... higher magnification and increased stereopsis, ... suited for detailed visualization to ... Retinal is ideal for vitrectomy ... peeling in proliferative vitreoretinopathy extending ...
Medicine Products: